Therapeutic Antibodies

HIV test
#FDA #HIV #Monoclonal antibodies #Theratechnologies

Results from HIV mAB intramuscular administration study 

Theratechnologies, a biopharmaceutical company focused on the development and commercialisation of innovative therapies, has announced results from a study evaluating an intramuscular (IM) method of administration for Trogarzo (ibalizumab-uiyk), a monoclonal antibody antiretroviral therapy (ART) for the treatment of heavily treatment-experienced adults with multidrug-resistant (MDR) HIV-1 infection failing their… Read More

#News

IgG1 monoclonal antibody
#Artificial intelligence (AI) #Aulos Bioscience #Monoclonal antibodies #Oncology #Phase I trial #Solid tumours

Data supports IgG1 monoclonal antibody for solid tumours

Aulos Bioscience has revealed new safety and efficacy data from the Phase I dose escalation portion of its Phase I/II clinical trial of AU-007 in patients with unresectable locally advanced or metastatic solid tumour cancers. The data will be presented at the Society for Immunotherapy of… Read More

#Cancer Research #News

FDA approval
#Biologics #FDA #Rare disease #Rocket Pharmaceuticals

FDA acceptance advances investigational gene therapy 

The US Food and Drug Administration (FDA) has accepted Rocket Pharmaceuticals’ Biologics License Application (BLA) and granted Priority Review for RP-L201 (marnetegragene autotemcel).  Rocket Pharmaceuticals is a late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need. RP-L201 is a lentiviral vector… Read More

#News #Regulatory

#Antibodies #Antibody drug conjugate (ADC) #CAR-T #Drug development #Drug discovery #Immunotherapy #Monoclonal antibodies

New DDW Highlights podcast: 2 October 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Immunotherapy has taken centre stage this week, with several announcements relating to… Read More

#News

Biologics research
#Biologics #Biologics / Biotechnology #Drug discovery #Infographic

Characterisation of candidates during biologic development

Download the new Infographic from NanoTemper: ‘Stability assessment of biologics during early development workflows‘. During early development of biologics, there are a large number of attributes researchers evaluate, but some of the most common centre around stability – asking if a biologic is well-folded, active and pure… Read More

#News

#Biologics #Biologics / Biotechnology #Drug discovery #Infographic

Stability assessment of biologics during early development workflows

During early development of biologics, there are a large number of attributes researchers evaluate, but some of the most common centre around stability – asking if a biologic is well-folded, active and pure in its buffer, and whether it remains that way over time. Biophysical characterisations are valuable for providing… Read More

#Intelligence #Resources

#Antibodies #Antibody drug conjugate (ADC) #CAR-T #Drug development #Drug discovery #Immunotherapy #Monoclonal antibodies

This week in drug discovery (25-29 September)  

News round-up for 25-29 September by DDW Digital Content Editor Diana Spencer. Immunotherapy has taken centre stage this week, with several announcements relating to regulatory approval, investment and research results for antibody and CAR-T therapies, perhaps most significantly, encouraging early-stage data for the first in vivo… Read More

#News

Monoclonal antibodies
#AbolerIS Pharma #Arthritis #Autoimmune disease #Financing #Monoclonal antibodies

€27.3M to advance monoclonal antibody for autoimmune diseases

AbolerIS Pharma has raised €27.3 million in a Series A financing led by Caixa Capital Risc and co-led by Sound Bioventures and Newton Biocapital. Proceeds from the financing will enable AbolerIS to accelerate the development of its lead programme in clinical trials and explore its effectiveness in additional autoimmune diseases. Read More

#Business & Investment #News

Antibodies
#Antibodies #Autoimmune disease #Collaboration #Ono Pharmaceutical #Twist Bioscience

Partners to discover antibodies for autoimmune diseases

Twist Bioscience and Ono Pharmaceutical will combine their efforts to discover and develop novel antibodies for the treatment of autoimmune diseases. Under the terms of the agreement, Twist will use its ‘Library of Libraries’ to conduct research activities to discover novel antibodies against targets identified by Ono. Twist also recently… Read More

#Business & Investment #News

#Antibodies #Antibody drug conjugate (ADC) #Collaboration #Partnership

Antibody development drives high-value biotech deals

The development of antibodies and associated technologies continues to drive high-value deals, according to a recent report in Nature.1 Using data provided by DealForma for the period 1 January 2022 to 16 June 2023, Nature analysed the deal trends in the field. In 2022, there were 156 antibody-focused deals with… Read More

#Editor's Choice #Market Reports #News

#Artificial intelligence (AI) #Breast cancer #Head and neck cancer #Immunotherapy #Long Covid #Monoclonal antibodies #Oncology #Parkinson's #Stem cells

New DDW Highlights podcast out now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week’s headline news features a stem-cell derived Parkinson’s therapy, a monoclonal antibody for… Read More

#News

#Artificial intelligence (AI) #Breast cancer #Head and neck cancer #Immunotherapy #Long Covid #Monoclonal antibodies #Oncology #Parkinson's #Stem cells

This week in drug discovery (28 August – 1 September)  

News round-up for 28 August – 1 September by DDW Digital Content Editor Diana Spencer. This week’s headline news features a stem-cell derived Parkinson’s therapy, a monoclonal antibody for head and neck cancer, an estrogen receptor degrader for breast cancer, a mitochondrial activator for long Covid,… Read More

#News

Monoclonal antibody
#Alentis Therapeutics #Cancer research #FDA #Head and neck cancer #Monoclonal antibodies #Oncology

FDA fast-tracks monoclonal antibody for head and neck cancer

Fast Track designation from the Food and Drug Administration (FDA) will accelerate the path to US submission for Alentis Therapeutics’ investigational monoclonal antibody. ALE.C04 is indicated to treat patients with recurrent or metastatic CLDN1-positive head and neck squamous cell carcinoma (HNSCC). Fast Track designation aims to facilitate the development and… Read More

#Editor's Choice #News #Regulatory

European Commission
#Bispecific Antibodies #EU #European Commission #Janssen #Myeloma #Oncology

“Important new approach” to myeloma now available in the EU

The European Commission (EC) has granted conditional marketing authorisation (CMA) for Janssen’s Talvey (talquetamab) as monotherapy for relapsed and refractory multiple myeloma (RRMM). It is approved in adult patients who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have… Read More

#News #Regulatory

Multiple myeloma
#Accelerated assessment #Bispecific Antibodies #FDA #Immunotherapy #Myeloma #Pfizer #Phase II trial

FDA accelerates approval for multiple myeloma immunotherapy

The US Food and Drug Administration (FDA) has granted accelerated approval to Pfizer’s Elrexfio (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM). The drug is approved in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory… Read More

#News #Regulatory

Antibody
#Acute inflammatory conditions #Antibody #Autoimmune disease #Biologics

Novel antibody displays potent anti-inflammatory activity

Researchers have shown that a novel antibody has greater activity and potentially fewer side effects than existing biological therapies for conditions such as rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD). The antibody, called Ab-IPL-IL-17, targets a specific section of signalling proteins IL-17A and IL-17F… Read More

#News